IPH Share Price

Open 12.42 Change Price %
High 12.50 1 Day -0.20 -1.61
Low 12.18 1 Week 0.02 0.16
Close 12.22 1 Month 0.17 1.41
Volume 169179 1 Year 1.54 14.42
52 Week High 15.83
52 Week Low 8.26
IPH Important Levels
Resistance 2 12.52
Resistance 1 12.39
Pivot 12.30
Support 1 12.05
Support 2 11.92
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
GSZ 17.56 3.97%
BRS 12.00 0.00%
BRS 12.00 0.00%
More..
EPA France Top Gainers Stocks
MLKRI 3.43 20.77%
APAM 33.78 15.72%
APAM 33.78 15.72%
MLLOI 3.80 15.15%
DEXB 17.47 13.89%
DEXB 17.47 13.89%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
More..
EPA France Top Losers Stocks
ALDOL 15.00 -58.32%
MLATV 2.00 -33.33%
MLPHW 0.70 -21.35%
MLNEI 0.91 -16.51%
ALALO 0.08 -11.11%
MLAAE 4.49 -9.84%
MLHMC 3610.00 -8.38%
MLDEX 1.50 -7.41%
FED 12.55 -6.90%
FED 12.55 -6.90%
More..

Innate Pharma SA (EPA: IPH)

IPH Technical Analysis 4
As on 23rd Jun 2017 IPH Share Price closed @ 12.22 and we RECOMMEND Buy for LONG-TERM with Stoploss of 11.92 & Strong Buy for SHORT-TERM with Stoploss of 11.62 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPH Target for June
1st Target up-side 13.13
2nd Target up-side 13.77
3rd Target up-side 14.4
1st Target down-side 11.33
2nd Target down-side 10.69
3rd Target down-side 10.06
IPH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.innate-pharma.com
IPH Address
IPH
117, Avenue de Luminy
Marseille, 13009
France
Phone: 33 4 30 30 30 30
Fax: 33 4 30 30 30 00
IPH Latest News
Innate Pharma acquires anti-C5aR, a first-in-class clinical-stage antibody ...   GlobeNewswire (press release)   - 03rd Jun 17
Innate Pharma to hold its Annual General Meeting of shareholders on June 23, 2017   GlobeNewswire (press release)   - 23rd May 17
INNATE PHARMA : 2016 reference document made available (in french)   GlobeNewswire (press release)   - 03rd Apr 17
Innate Pharma investor conference call on November 14, 2016 to discuss recent ...   GlobeNewswire (press release)   - 10th Nov 16
INNATE PHARMA: Preliminary safety and clinical activity results for IPH4102 to ...   GlobeNewswire (press release)   - 13th Oct 16
AACR 2016: Innate Pharma displays broad innovative pipeline in immuno-oncology   GlobeNewswire (press release)   - 17th Mar 16
Sanofi and Innate Pharma Collaborate on New Bispecific NK Cell Engagers in ...   GlobeNewswire (press release)   - 11th Jan 16
Innate Pharma and AstraZeneca announce global agreement for IPH2201 in immuno ...   GlobeNewswire (press release)   - 24th Apr 15
INNATE PHARMA : appoints Nicolai Wagtmann Chief Scientific Officer   GlobeNewswire (press release)   - 02nd Oct 13
BMS Pays Innate Pharma $35M Up Front for Global Rights to Clinical-Stage ...   Genetic Engineering News   - 07th Jul 11
Interactive Technical Analysis Chart Innate Pharma SA ( IPH EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Innate Pharma SA
IPH Business Profile
Innate Pharma S.A., a biopharmaceutical company, engages in the development of immunotherapy drug candidates for cancer and inflammatory diseases. The company primarily develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors (KIR) in Phase II trials for acute myeloid leukemia and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab respectively; and IPH2201/NN8765, an anti-NKG2A antibody in Phase I clinical trials for the treatment of inflammatory conditions and autoimmune diseases, and in rheumatoid arthritis. The company’s pre-clinical product candidates include IPH41, a cytotoxic mAb that targets KIR3DL2, an inhibitory receptor of NK cells; and IPH33, a blocking mAb targeting TLR3, an inducer of Type I IFN and pro-inflammatory cytokines. It has licensing agreements with Bristol-Myers Squibb for the development of IPH2102; and Novo Nordisk A/S for the development of IPH2201. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.